Volume 5, Issue 3 (9-2023)
sjmshm 2023, 5(3): 1-5 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Amini J, Sepehri Roushan Z, Mohammadalizadeh O, Bibak B. Evaluation of Δ9-tetrahydrocannabinol Effect on Autism Inflammatory Factors by Molecular Docking Study. sjmshm 2023; 5 (3) :1-5
URL: http://sjmshm.srpub.org/article-3-189-en.html
URL: http://sjmshm.srpub.org/article-3-189-en.html
Department of Medical Biotechnology and Molecular Science, North Khorasan University of Medical Science, Bojnurd, Iran.
Abstract: (323 Views)
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder and is characterised by social communication difficulties. Inflammation and immune system activation is reported as pathogenicity of ASD. It has been demonstrated that cannabis consumption improves interpersonal communication and reduces hostile feelings. In this study, we evaluated the beneficial effect of Δ9-tetrahydrocannabinol (THC) on ASD’s inflammatory factors with bioinformatic tools. Molecular docking showed THC interact with ASD’s inflammatory factors specially IL12B and RELA. It seems that THC alleviates inflammation in ASD by targeting ASD’s inflammatory factors.
Type of Study: Research |
Subject:
Pharmacology, Toxicology and Pharmaceutics (General)
Received: 2023/06/18 | Revised: 2023/08/24 | Accepted: 2023/09/5 | Published: 2023/09/25
Received: 2023/06/18 | Revised: 2023/08/24 | Accepted: 2023/09/5 | Published: 2023/09/25
References
1. Oakley B, Loth E, Murphy DG. Autism and mood disorders. Int Rev Psychiatr. 2021; 33(3): 280-299. [DOI:10.1080/09540261.2021.1872506] [PMID]
2. Xu W, Yao J, Liu W. Intervention effect of sensory integration training on the behaviors and quality of life of children with autism. Psychiatr Danub. 2019; 31(3): 340-346. [DOI:10.24869/psyd.2019.340] [PMID]
3. Kang DW, Adams JB, Coleman DM, Pollard EL, Maldonado J, McDonough-Means S, et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci Rep. 2019; 9(1): 5821. [DOI:10.1038/s41598-019-42183-0] [PMID]
4. Jiang NM, Cowan M, Moonah SN, Petri WA Jr. The impact of systemic inflammation on neurodevelopment. Trend Mol Med. 2018; 24(9): 794-804. [DOI:10.1016/j.molmed.2018.06.008] [PMID]
5. Turbé H, Waeckel L, Dechelotte B. Overview of prospects for inflammation pathways in autism spectrum disorders. Encephale. 2020; 46(5): 404-407. [DOI:10.1016/j.encep.2019.09.006] [PMID]
6. Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021; 12(1): 6. [DOI:10.1186/s13229-021-00420-2] [PMID]
7. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2018; 9: 1521. [DOI:10.3389/fphar.2018.01521] [PMID]
8. Beydogan AB, Coskun ZM, Bolkent S. The protective effects of Δ(9) -tetrahydrocannabinol against inflammation and oxidative stress in rat liver with fructose-induced hyperinsulinemia. J Pharm Pharmacol. 2019; 71(3): 408-416. [DOI:10.1111/jphp.13042] [PMID]
9. Prata J, Machado AS, von Doellinger O, Almeida MI, Barbosa MA, Coelho R, et al. The contribution of inflammation to autism spectrum disorders: recent clinical evidence. Method Mol Biol. 2019; 2011: 493-510. [DOI:10.1007/978-1-4939-9554-7_29] [PMID]
10. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acid Res. 2021; 49(D1): D605-d12. [DOI:10.1093/nar/gkaa1074] [PMID]
11. Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acid Res. 2018; 46(D1): D380-d6. [DOI:10.1093/nar/gkx1013] [PMID]
12. Famitafreshi H, Karimian M. Overview of the recent advances in pathophysiology and treatment for autism. CNS Neurol Disord Drug Target. 2018; 17(8): 590-594. [DOI:10.2174/1871527317666180706141654] [PMID]
13. Mottron L, Bzdok D. Autism spectrum heterogeneity: fact or artifact? Mol Psychiatr. 2020; 25(12): 3178-3185. [DOI:10.1038/s41380-020-0748-y] [PMID]
14. Freitas BC, Mei A, Mendes APD, Beltrão-Braga PCB, Marchetto MC. Modeling inflammation in autism spectrum disorders using stem cells. Front Pediatr. 2018; 6: 394. [DOI:10.3389/fped.2018.00394] [PMID]
15. Matta SM, Hill-Yardin EL, Crack PJ. The influence of neuroinflammation in autism spectrum disorder. Brain Behav Immun. 2019; 79: 75-90. [DOI:10.1016/j.bbi.2019.04.037] [PMID]
16. Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid delivery systems for pain and inflammation treatment. molecules. 2018; 23(10). [DOI:10.3390/molecules23102478] [PMID]
17. Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. Faseb J. 2016; 30(11): 3682-3689. [DOI:10.1096/fj.201600646R] [PMID]
18. Zhao J, Tian M, Zhang S, Delfarah A, Gao R, Rao Y, et al. Deamidation Shunts RelA from mediating inflammation to aerobic glycolysis. Cell Metab. 2020; 31(5): 937-55.e7. [DOI:10.1016/j.cmet.2020.04.006] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |